{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:32:14Z","timestamp":1781649134193,"version":"3.54.5"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,20]]},"DOI":"10.7759\/cureus.107424","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T03:00:17Z","timestamp":1776740417000},"source":"Crossref","is-referenced-by-count":1,"title":["Hypofibrinogenemia Induced by Eravacycline: A Rare but Serious Adverse Effect of a Novel Antimicrobial Agent"],"prefix":"10.7759","author":[{"given":"Pradeep","family":"Khanal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhail","family":"Sapkota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Karageorgiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tareq","family":"Al Baghdadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0545-8","article-title":"Review of eravacycline, a novel fluorocycline antibacterial agent","volume":"76","author":"Zhanel GG","year":"2016","unstructured":"Zhanel GG, Cheung D, Adam H, et al.. Review of eravacycline, a novel fluorocycline antibacterial agent. Drugs. 2016, 76:567-88. 10.1007\/s40265-016-0545-8","journal-title":"Drugs"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1177\/1060028019850173","article-title":"Eravacycline: the tetracyclines strike back","volume":"53","author":"Heaney M","year":"2019","unstructured":"Heaney M, Mahoney MV, Gallagher JC. Eravacycline: the tetracyclines strike back. Ann Pharmacother. 2019, 53:1124-35. 10.1177\/1060028019850173","journal-title":"Ann Pharmacother"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01614-13","article-title":"Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections","volume":"58","author":"Solomkin JS","year":"2014","unstructured":"Solomkin JS, Ramesh MK, Cesnauskas G, et al.. Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections. Antimicrob Agents Chemother. 2014, 58:1847-54. 10.1128\/AAC.01614-13","journal-title":"Antimicrob Agents Chemother"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2016.4237","article-title":"Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the investigating gram-negative infections treated with eravacycline (IGNITE 1) trial: a randomized clinical trial","volume":"152","author":"Solomkin J","year":"2017","unstructured":"Solomkin J, Evans D, Slepavicius A, et al.. Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the investigating gram-negative infections treated with eravacycline (IGNITE 1) trial: a randomized clinical trial. JAMA Surg. 2017, 152:224-32. 10.1001\/jamasurg.2016.4237","journal-title":"JAMA Surg"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.943674","article-title":"Incidence, characteristics and risk factors of hypofibrinogenemia associated with tigecycline: A multicenter retrospective study in China","volume":"13","author":"Leng B","year":"2022","unstructured":"Leng B, Shen C, Gao T, et al.. Incidence, characteristics and risk factors of hypofibrinogenemia associated with tigecycline: A multicenter retrospective study in China. Front Pharmacol. 2022, 13:943674. 10.3389\/fphar.2022.943674","journal-title":"Front Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s12959-022-00369-z","article-title":"Coagulation dysfunction events associated with tigecycline: a real-world study from FDA adverse event reporting system (FAERS) database","volume":"20","author":"Guo M","year":"2022","unstructured":"Guo M, Liang J, Li D, Zhao Y, Xu W, Wang L, Cui X. Coagulation dysfunction events associated with tigecycline: a real-world study from FDA adverse event reporting system (FAERS) database. Thromb J. 2022, 20:12. 10.1186\/s12959-022-00369-z","journal-title":"Thromb J"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac591","article-title":"Eravacycline associated hypofibrinogenemia: a case series of transplant patients with Mycobacterium abscessus infections and review of literature","volume":"9","author":"Rausch E","year":"2022","unstructured":"Rausch E, Vemuri K, Anderman TM, et al.. Eravacycline associated hypofibrinogenemia: a case series of transplant patients with Mycobacterium abscessus infections and review of literature. Open Forum Infect Dis. 2022, 9:ofac591. 10.1093\/ofid\/ofac591","journal-title":"Open Forum Infect Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-019-00912-5","article-title":"Tigecycline-induced coagulopathy: a literature review","volume":"41","author":"Cui N","year":"2019","unstructured":"Cui N, Cai H, Li Z, Lu Y, Wang G, Lu A. Tigecycline-induced coagulopathy: a literature review. Int J Clin Pharm. 2019, 41:1408-13. 10.1007\/s11096-019-00912-5","journal-title":"Int J Clin Pharm"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000022638","article-title":"Hypofibrinogenemia induced by high-dose tigecycline-case report and review of literature","volume":"99","author":"Fan Q","year":"2020","unstructured":"Fan Q, Huang W, Weng Y, Xie X, Shi Z. Hypofibrinogenemia induced by high-dose tigecycline-case report and review of literature. Medicine (Baltimore). 2020, 99:e22638. 10.1097\/MD.0000000000022638","journal-title":"Medicine (Baltimore)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkag030","article-title":"Impact of eravacycline on fibrinogen","volume":"81","author":"Stevenson E","year":"2026","unstructured":"Stevenson E, Ponder M, Daniels L, Jones T, Bartelt L, Van Duin D, Footer B. Impact of eravacycline on fibrinogen. J Antimicrob Chemother. 2026, 81:dkag030. 10.1093\/jac\/dkag030","journal-title":"J Antimicrob Chemother"},{"key":"ref11","unstructured":"XERAVA (eravacycline) for injection. prescribing information. (2018). Accessed: March 31, 2025: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/211109s014lbl.pdf."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/484207-hypofibrinogenemia-induced-by-eravacycline-a-rare-but-serious-adverse-effect-of-a-novel-antimicrobial-agent","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T03:00:27Z","timestamp":1776740427000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/484207-hypofibrinogenemia-induced-by-eravacycline-a-rare-but-serious-adverse-effect-of-a-novel-antimicrobial-agent"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.107424","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,20]]}}}